OIA
OVID icon

Optimum Investment Advisors’s Ovid Therapeutics OVID Stock Holding History

Optimum Investment Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,000
Closed -$4K – 863
2022
Q2 		$4K Hold
2,000
– – ﹤0.01% 712
2022
Q1 		$6K Buy
2,000
+1,000
+100% +$3.15K ﹤0.01% 713
2021
Q4 		$3K Hold
1,000
– – ﹤0.01% 768
2021
Q3 		$3K Buy
+1,000
New +$3.65K ﹤0.01% 786

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Optimum Investment Advisors's OVID Position: Q3 2022 in Review

Optimum Investment Advisors sold out of Ovid Therapeutics (OVID) in Q3 2022, closing a stake of 2,000 shares — an estimated $4K sold.

Optimum Investment Advisors first reported a position in OVID in Q3 2021 and held it in 4 quarters. The position peaked at $6K in Q1 2022. 59 funds tracked by Wall St. Rank hold OVID as of Q3 2022.

  • Optimum Investment Advisors reported no remaining Ovid Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Optimum Investment Advisors sold 2,000 Ovid Therapeutics shares in Q3 2022, an estimated $4K.
  • Optimum Investment Advisors first reported a position in Ovid Therapeutics in Q3 2021 and held it in 4 quarters.
  • Optimum Investment Advisors's Ovid Therapeutics position peaked at $6K in Q1 2022.
  • 59 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2022.

Based on Optimum Investment Advisors's 13F filing for Q3 2022, filed 24 Oct 2022.